2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4

Abecma (TSVT) is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb (BMY) and 2seventy bio. Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S. The companies’ broad clinical development program for Abecma includes ongoing and planned clinical studies, KarMMa-2, KarMMa-3, KarMMa-9, in earlier lines of treatment for patients with multiple myeloma…Abecma generated $56M U.S. commercial revenue in the fourth quarter of 2023 and $358M for the full year, shared equally with Bristol Myers Squibb